Cardiotoxicity associated with Herceptin (trastuzumab) therapy: A potential mechanism

被引：0
|
作者：
Zuppinger, C
Sawyer, DB
Miller, T
Eppenberger, HM
Suter, TM
机构：
[1] Univ Hosp Bern, CH-3010 Bern, Switzerland
[2] Boston Univ, Dept Med, Myocardial Biol Unit, Boston, MA 02215 USA
[3] Fed Inst Technol ETH, Inst Cell Biol, Zurich, Switzerland
来源：
EUROPEAN JOURNAL OF CANCER | 2002年 / 38卷
关键词：
D O I：
10.1016/S0959-8049(02)80300-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
214
引用
收藏
页码：S96 / S96
页数：1
相关论文
共 50 条
  • [41] Trastuzumab -: Herceptin® -: Oncolytic -: Monoclonal antibody
    不详
    DRUGS OF THE FUTURE, 2000, 25 (10) : 1109 - 1111
  • [42] Cardiotoxicity profile of trastuzumab
    Ewer, Steven M.
    Ewer, Michael S.
    DRUG SAFETY, 2008, 31 (06) : 459 - 467
  • [43] Antioxidant Protection against Trastuzumab Cardiotoxicity in Breast Cancer Therapy
    Mendez-Valdes, Gabriel
    Gomez-Hevia, Francisca
    Bragato, Maria Chiara
    Lillo-Moya, Jose
    Rojas-Sole, Catalina
    Saso, Luciano
    Rodrigo, Ramon
    ANTIOXIDANTS, 2023, 12 (02)
  • [44] Risk factors for the occurrence and irreversibility of cardiotoxicity caused by trastuzumab therapy
    Gabric, I. D.
    Vazdar, L. J.
    Pintaric, H.
    Planinc, D.
    Stefanovic, M.
    Trbusic, M.
    Vinter, O.
    Jazvic, M.
    Soldic, Z.
    Separovic, R.
    EUROPEAN JOURNAL OF HEART FAILURE, 2015, 17 : 26 - 26
  • [45] Cardiotoxicity Profile of Trastuzumab
    Steven M. Ewer
    Michael S. Ewer
    Drug Safety, 2008, 31 : 459 - 467
  • [46] Cardiotoxicity Associated Trastuzumab and Anthracyclines in Treating Breast Cancer Patients
    Al-Ali, Basheer Akeel
    Hatef, Zahraa S.
    Mohammed, Haithem Rauf
    LATIN AMERICAN JOURNAL OF PHARMACY, 2021, 40 (SI): : 135 - 140
  • [47] A Case of Trastuzumab-Associated Cardiomyopathy Presenting as an Acute Coronary Syndrome: Acute Trastuzumab Cardiotoxicity
    Hidalgo, Sylvana
    Albright, Carol A.
    Wells, Gretchen L.
    CASE REPORTS IN CARDIOLOGY, 2013, 2013
  • [48] Reversible cardiotoxicity from pegylated liposomal doxorubicin plus trastuzumab (Herceptin): results from 2 prospective studies.
    Kim, E
    Gaiotti, DA
    Volm, MD
    Freedberg, RS
    Muggia, FM
    Vogel, CL
    Panasci, L
    Clemons, M
    Martin, LA
    Chia, SK
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S204 - S204
  • [49] Application and potential limitations of animal models utilized in the development of trastuzumab (Herceptin®):: A case study
    Pegram, Mark
    Ngo, Debbie
    ADVANCED DRUG DELIVERY REVIEWS, 2006, 58 (5-6) : 723 - 734
  • [50] Transforming growth factor-beta down-regulation: a potential novel mechanism of trastuzumab (herceptin) resistance in breast cancer cells
    Nahta, R
    Esteva, FJ
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S88 - S88
12345